Amount for accounts payable offset by advance.

No definition available.

Name:	nnvc_AccountsPayableOffsetByAdvance
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of clinical trial and other costs accrued

+ References

No definition available.

+ Details

Name:	nnvc_AccruedClinicalTrialAndOtherCosts
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet).

+ References

No definition available.

+ Details

Name:	nnvc_AccruedClinicalTrialCosts
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

+ References

No definition available.

+ Details

Name:	nnvc_ClinicalTrialRelatedToOtherCostsCharges
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payment due.

+ References

No definition available.

+ Details

Name:	nnvc_MilestonePaymentAmountDue
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of shares authorized for license milestone payment.

+ References

No definition available.

+ Details

Name:	nnvc_NumberOfSharesAuthorizedForLicenseMilestonePayment
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The percentage of direct costs.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfDirectCosts
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty expense calculated as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalties on sales.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfRoyaltiesOnSales
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares issued during the period for license agreement.

+ References

No definition available.

+ Details

Name:	nnvc_SeriesPreferredSharesIssuedDuringPeriodForLicenseAgreement
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of stock issued during period shares new issues principle of note convertible.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

+ Details

Name:	us-gaap_AccountsPayableCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentConvertibleStockPriceTrigger
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481303/470-50-40-4

+ Details

Name:	us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-6

+ Details

Name:	us-gaap_InterestExpenseDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The effective interest rate during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_LineOfCreditFacilityInterestRateDuringPeriod
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of general and administrative expense classified as other.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nnvc_Covid19LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=nnvc_Dr.AnilDiwanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nnvc_KarveerMeditechPvt.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=nnvc_UnsecuredPromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions (Details) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended
Related Party Transactions (Details) - USD ($)	Nov. 13, 2023	Oct. 27, 2023	Jul. 19, 2023	Jan. 27, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 19, 2023	Sep. 09, 2021
Related Party Transaction
Royalties on sales (in percent)							70.00%
Research and Development Costs Related Party					$ 1,573,879	$ 1,170,710	$ 3,040,544	$ 2,283,369
Interest expense					13,000		50,000
Related party
Related Party Transaction
Account Payable - Related Party					504,039		504,039		$ 233,434
COVID 19 License Agreement \| Related party
Related Party Transaction
Research and Development Costs Related Party									157,000
Milestone payment amount due											$ 1,500,000
Line of credit agreement \| Dr. Anil Diwan
Related Party Transaction
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Fixed rate of interest on the amount drawn under the line of credit facility	12.00%
KMPL
Related Party Transaction
Account Payable - Related Party					172,812		$ 172,812
Royalties on sales (in percent)							70.00%
Clinical trial related and other costs					150,000		$ 365,000
KMPL \| Related party
Related Party Transaction
Accrued clinical trial related and other costs					150,000				100,000
Clinical trial Costs Accrued - Related Party					150,000		365,000
TheraCour Pharma Inc
Related Party Transaction
Account Payable - Related Party					331,227		$ 331,227			$ 233,434
Percentage of direct costs							30.00%
Other general and administrative expense							$ 2,000
Percentage of net sales allocated for royalty payments (in percent)							15.00%
Accounts payable					831,227		$ 831,227		733,434
Accounts payable offset by advance					500,000		500,000		500,000
Accrued royalties					0		0		$ 0
Research and Development Costs Related Party					$ 682,258	$ 633,247	1,321,335	$ 1,245,958
TheraCour Pharma Inc \| Related party
Related Party Transaction
Number of shares upon principle of note convertible		331,859
Gain on extinguishment							$ 50,000
TheraCour Pharma Inc \| COVID 19 License Agreement \| Related party
Related Party Transaction
Research and Development Costs Related Party										$ 935,088
Unsecured promissory note \| TheraCour Pharma Inc \| Related party
Related Party Transaction
Interest rate per annum (as a percent)			12.00%
Series A Preferred stock \| COVID 19 License Agreement \| Related party
Related Party Transaction
Shares issued for milestone payment				50,000
Series A Preferred stock \| TheraCour Pharma Inc
Related Party Transaction
Number of shares upon principle of note convertible			331,859
Debt instrument, conversion stock, par value			$ 0.00001
Series A Preferred stock \| TheraCour Pharma Inc \| COVID 19 License Agreement \| Related party
Related Party Transaction
Number of shares authorized for license milestone payment												100,000